PDF(Pubmed)
Abstract：
The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a significant number of cases and deaths worldwide. Vaccination is the most effective preventive measure against the disease. This study aimed to assess the mortality rates of COVID-19 patients in the United States and the effectiveness of Pfizer (Pfizer, NY, USA), Moderna (Moderna, MA, USA), and Janssen (Johnson & Johnson, NJ, USA) vaccines in preventing mortality. A systematic review and meta-analysis were conducted following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA-2020) guidelines. Eligible studies reporting on the effectiveness of COVID-19 vaccines on patient outcomes were included. The search was performed in PubMed, Cochrane, and Google Scholar databases. The data were extracted, and risk ratios (RR) were calculated for mortality outcomes. The analysis was performed using Review Manager software, and bias assessments were conducted using the Joanna Briggs Institute (JBI) Meta-Analysis tools. A total of seven studies with 21,618,297 COVID-19 patients were included in the meta-analysis. The odds ratio (OR) for mortality among unvaccinated patients compared to vaccinated patients was 2.46 (95% CI: 1.71-3.53), indicating that unvaccinated patients were 2.46 times more likely to die from COVID-19. The findings of this study support the effectiveness of COVID-19 vaccination in reducing mortality among infected individuals. Unvaccinated patients had a significantly higher risk of mortality compared to vaccinated patients. Vaccination remains a crucial strategy to mitigate the severity of the disease and reduce mortality rates. Efforts should be made to address vaccine hesitancy and ensure widespread vaccine coverage.
摘要：
由严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）引起的COVID-19大流行在全球范围内导致了大量病例和死亡。接种疫苗是预防这种疾病最有效的措施。这项研究旨在评估美国COVID-19患者的死亡率和辉瑞(辉瑞，NY,美国),Moderna(Moderna,MA,美国),和詹森（约翰逊和约翰逊，NJ,美国)预防死亡的疫苗。根据系统评价和荟萃分析的首选报告项目（PRISMA-2020）指南进行系统评价和荟萃分析。纳入了报告COVID-19疫苗对患者预后有效性的合格研究。搜索是在PubMed中进行的，科克伦,和谷歌学者数据库。数据被提取出来,并计算死亡结局的风险比(RR).使用ReviewManager软件进行分析,使用乔安娜·布里格斯研究所（JBI）的荟萃分析工具进行偏倚评估。共有7项研究纳入荟萃分析，其中21,618,297例COVID-19患者。与未接种疫苗的患者相比，未接种疫苗的患者死亡率的比值比（OR）为2.46（95％CI：1.71-3.53），表明未接种疫苗的患者死于COVID-19的可能性是其2.46倍。这项研究的结果支持了COVID-19疫苗接种在降低感染者死亡率方面的有效性。与接种疫苗的患者相比，未接种疫苗的患者死亡风险明显更高。疫苗接种仍然是减轻疾病严重程度和降低死亡率的关键策略。应努力解决疫苗犹豫的问题，并确保广泛的疫苗覆盖率。
